Giuseppe G. Loscocco

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia.

Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia.

Journal: American journal of hematology

Published: May 20, 2026

Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities.

Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities.

Journal: American journal of hematology

Published: April 08, 2026

Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.

Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.

Journal: Blood cancer journal

Published: March 30, 2026

Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera.

Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera.

Journal: Blood neoplasia

Published: February 09, 2026

Differential Diagnosis of Eosinophilic Lung Diseases.

Differential Diagnosis of Eosinophilic Lung Diseases.

Journal: The journal of allergy and clinical immunology. In practice

Published: January 12, 2026

Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers.

Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers.

Journal: Current hematologic malignancy reports

Published: November 20, 2025

Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency.

Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency.

Journal: Haematologica

Published: November 18, 2025

Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models.

Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models.

Journal: Expert review of molecular diagnostics

Published: October 11, 2025

Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images.

Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images.

Journal: Leukemia

Published: August 20, 2025

A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.

A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm.

Journal: American journal of hematology

Published: August 14, 2025

Triple A Plus (AAA +) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients.

Triple A Plus (AAA +) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients.

Journal: American journal of hematology

Published: August 06, 2025

Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis Score in Primary Myelofibrosis.

Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis Score in Primary Myelofibrosis.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: April 07, 2025

Showing 1-12 of 75

Last Updated: 09/26/2026